Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038QTORIN™ rapamycin has the potential to be ...

Researchers from the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) have described a new mechanism ...

We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC ® small molecules toward key clinical milestones,” said Pratik Shah, Ph.D., ...

Protagonist Therapeutics, Inc. (”Protagonist” or the “Company”), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that ...

Learn about Brink Therapeutics as it raises $4 million to go beyond CRISPR with engineered recombinases in CAR T therapy.

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...